摘要
目的:应用小剂量环磷酰胺(CTX)联合参一胶囊治疗IIII、V期非小细胞肺癌,观察其临床疗效及毒副作用。方法:III、IV期非小细胞肺癌患者经标准化、放疗后随机分为两组,治疗组(38例):CTX 50mg每日一次、参一胶囊20mg每日两次口服,三至六个月;对照组(34例):化疗后不用任何药物治疗。结果:联合治疗组患者外周血血管内皮生长因子(VEGF)表达下降,T淋巴细胞亚群CD4+及CD4+/CD8+升高,病人生存质量及生存期提高。结论:III、IV期NSCLC患者化疗后联合应用小剂量CTX联合参一胶囊治疗是一种安全有效的治疗方法,可以提高患者的生存质量及生存期。
Objective： To investigate its toxicity and efficacy of low - dose cyclophesphamide（CTX） and ginsenoside Rg3 in treating patients with advanced non-small cell lung cancer. Methods： 72 patients with non-small cell lung cancer, who were diagnosed Stage Ⅲ or Ⅳ by pathology and had been treated with chemotherapy and radiotherapy,were randomly divided into two groups; the therapeutic group（n = 38） was given CTX 50mg qd po plus ginsenoside Rg3 20mg bid po for three to six months; the control group wasn＇t given any medication after chemotherapy. The clinical data of all the patients in the two groups were analysed when and after medication. Results： The results showed that in the therapeutic group, TTP（ = tumor time of progression） was 7 months and meso life span was 19.5 months and annual survival rate was 63.2% ; while in the control group, TTP4 months and meso life span 13.5% and annual survival rate 52.9%. The serum VEGF（ = vascular endothelial growth factor） in the therapeutic group was lower than that in the control group after medication. CD4 ＋ , CD4 ＋/CD8 ＋ after treatment in the therapeutic group were higher than those before treatment. Conclusion： This experiment is proved to be a new safe antieancer therapy,which can improve life quality of the patients and prolong their life span.
出处
《现代生物医学进展》
CAS
2006年第2期50-52,共3页
Progress in Modern Biomedicine
